COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) Short Interest Update

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) was the recipient of a large growth in short interest during the month of January. As of January 30th, there was short interest totaling 6,208,105 shares, a growth of 23.3% from the January 15th total of 5,033,852 shares. Based on an average trading volume of 1,236,585 shares, the short-interest ratio is presently 5.0 days. Currently, 6.7% of the company’s shares are short sold. Currently, 6.7% of the company’s shares are short sold. Based on an average trading volume of 1,236,585 shares, the short-interest ratio is presently 5.0 days.

Hedge Funds Weigh In On COMPASS Pathways

A number of large investors have recently bought and sold shares of the business. Nantahala Capital Management LLC boosted its position in COMPASS Pathways by 47.7% during the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock valued at $11,704,000 after acquiring an additional 1,350,698 shares in the last quarter. Millennium Management LLC lifted its stake in shares of COMPASS Pathways by 39.9% during the 3rd quarter. Millennium Management LLC now owns 2,715,872 shares of the company’s stock worth $15,562,000 after purchasing an additional 774,090 shares during the last quarter. ARK Investment Management LLC lifted its stake in shares of COMPASS Pathways by 1.6% during the 4th quarter. ARK Investment Management LLC now owns 2,156,012 shares of the company’s stock worth $14,876,000 after purchasing an additional 34,894 shares during the last quarter. UBS Group AG boosted its position in COMPASS Pathways by 27.7% during the third quarter. UBS Group AG now owns 2,144,410 shares of the company’s stock valued at $12,287,000 after purchasing an additional 465,802 shares in the last quarter. Finally, Jefferies Financial Group Inc. grew its stake in COMPASS Pathways by 14.5% in the fourth quarter. Jefferies Financial Group Inc. now owns 1,576,905 shares of the company’s stock valued at $10,881,000 after purchasing an additional 200,000 shares during the last quarter. Institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Trading Down 0.7%

NASDAQ CMPS opened at $5.81 on Tuesday. COMPASS Pathways has a one year low of $2.25 and a one year high of $8.20. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.23 and a current ratio of 1.23. The company has a market capitalization of $557.88 million, a price-to-earnings ratio of -2.14 and a beta of 1.92. The company’s 50-day simple moving average is $6.74 and its two-hundred day simple moving average is $5.87.

Analyst Ratings Changes

Several equities analysts have commented on the company. Morgan Stanley upped their price objective on COMPASS Pathways from $10.00 to $11.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of COMPASS Pathways in a report on Wednesday, January 21st. Royal Bank Of Canada raised their price target on shares of COMPASS Pathways from $16.00 to $21.00 and gave the stock an “outperform” rating in a research note on Friday, January 23rd. Compass Point set a $15.00 price objective on shares of COMPASS Pathways in a research report on Thursday. Finally, Lifesci Capital raised shares of COMPASS Pathways to a “strong-buy” rating in a research report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.11.

COMPASS Pathways Company Profile

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.